SENL-103

N/A

Report date: 2026/02/25 20:02:36

Base Information

Drug NameSENL-103
Drug Alias NameSENL-103S-103
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsAmyloidosisMultiple SclerosisMyasthenia Gravis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHebei Senlang Biological Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHebei Senlang Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsAmyloidosisMultiple SclerosisMyasthenia Gravis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A